AKYA vs. QTRX, FEIM, RPID, SEER, OWLT, PRE, KEQU, NAUT, INTT, and ODYS
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Quanterix (QTRX), Frequency Electronics (FEIM), Rapid Micro Biosystems (RPID), Seer (SEER), Owlet (OWLT), Prenetics Global (PRE), Kewaunee Scientific (KEQU), Nautilus Biotechnology (NAUT), inTEST (INTT), and Odysight.ai (ODYS). These companies are all part of the "measuring and control equipment" industry.
Akoya Biosciences vs. Its Competitors
Akoya Biosciences (NASDAQ:AKYA) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
Akoya Biosciences presently has a consensus target price of $2.51, suggesting a potential upside of 89.85%. Quanterix has a consensus target price of $15.60, suggesting a potential upside of 133.18%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Akoya Biosciences.
Quanterix has higher revenue and earnings than Akoya Biosciences. Quanterix is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Quanterix has a net margin of -36.82% compared to Akoya Biosciences' net margin of -59.44%. Quanterix's return on equity of -15.07% beat Akoya Biosciences' return on equity.
In the previous week, Akoya Biosciences had 2 more articles in the media than Quanterix. MarketBeat recorded 3 mentions for Akoya Biosciences and 1 mentions for Quanterix. Quanterix's average media sentiment score of 1.87 beat Akoya Biosciences' score of 0.63 indicating that Quanterix is being referred to more favorably in the news media.
79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 7.3% of Akoya Biosciences shares are owned by company insiders. Comparatively, 6.9% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Quanterix beats Akoya Biosciences on 11 of the 16 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:AKYA) was last updated on 7/2/2025 by MarketBeat.com Staff
